SEOUL, Feb. 6 (Korea Bizwire) — Korean scientists have identified a molecular switch that could potentially transform cancer cells back into normal cells by capturing the critical transition moment when healthy cells become cancerous, the Korea Advanced Institute of Science and Technology (KAIST) announced on February 5. The research team, led by Cho Kwang-hyun from the [...]
SEOUL, Jan. 31 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Friday its new biosimilar for an autoimmune disease treatment has received approval from the U.S. Food and Drug Administration (FDA). The FDA approved Celltrion’s Avtozma, a biosimilar to Actemra, in both intravenous and subcutaneous formulations, according to the company. Avtozma [...]
SEOUL, Jan. 30 (Korea Bizwire) — South Korean drug manufacturers are rapidly expanding their presence in the global autoimmune disease treatment market, challenging the longtime dominance of Western pharmaceutical giants. Autoimmune diseases, which occur when the body’s immune system mistakenly attacks its own organs, tissues, and cells, encompass a range of conditions including rheumatoid arthritis, multiple sclerosis, [...]
SEOUL, Jan. 24 (Korea Bizwire) — The South Korean government has announced an ambitious initiative to position the country as one of the world’s top five biotech powerhouses by establishing a Korean-style bio cluster and accelerating AI- and data-driven biotech research and development (R&D). The plan aims to elevate the biotech industry to a level [...]
SEOUL, Jan. 23 (Korea Bizwire) — Health and medical advertisers dominated South Korean television advertising last year, according to a comprehensive industry report released January 22 by data platform company IGAWorks. The report shows that health and medical sector advertisements accounted for 24% of total TV advertising impressions in 2024, reaching 136 billion views. This placed [...]
SEOUL, Jan. 23 (Korea Bizwire) — Celltrion Inc.’s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company said Thursday. SteQeyma, an ustekinumab biosimilar treatment for multiple chronic inflammatory diseases, was released in France on Monday (local time), following its launch in Italy and Spain earlier this month, according to [...]
SEOUL, Jan. 15 (Korea Bizwire) – SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major South American biopharma, Eurofarma, in the United States to expand its business there, company officials said Wednesday. The company announced the plan during the ongoing JP Morgan Healthcare Conference in [...]
SEOUL, Jan. 14 (Korea Bizwire) — Samsung Biologics Co., a biotech arm of South Korea’s Samsung Group, said Tuesday it has received a contract manufacturing deal worth 2.07 trillion won (US$1.4 billion) from a Europe-based biopharmaceutical firm. In the largest-ever contract manufacturing deal, Samsung Biologics will manufacture a biomedicine for the European company from Dec. [...]
SEOUL, Jan. 7 (Korea Bizwire) — As aging populations and chronic illnesses drive a shift in global healthcare toward prevention and cost reduction, traditional medicine is emerging as a growing export opportunity, according to a report released by the Korea International Trade Association (KITA) on January 6. The report, titled “The Era of Global Traditional [...]
SEOUL, Jan. 2 (Korea Bizwire) — The Ministry of Food and Drug Safety (MFDS) announced significant reforms to streamline drug approval processes in 2025, including reducing the time required for registering imported active pharmaceutical ingredients (APIs) and simplifying compliance procedures for low-risk manufacturers. A dedicated task force will now handle new drug approvals, increasing company consultations [...]